Absci is trading 5.21% higher at $8.68 in pre-market on October 19, with no new company announcement found to explain the move. - Shares closed at $8.25 on October 16. - KeyBanc raised its price target to $20 from $16 on October 16, but shares fell that session, so the earlier action does not clearly explain Monday’s gain. - Absci’s investor-relations page lists its next business update and Q3 results for November 12. Reported biotech-sector weakness was inconsistent with Absci’s move.